| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:VTP50469 mesylate
CAS:2169919-27-9
Package:25mg/RMB 17200;50mg/RMB 22800;100mg/RMB 29500
|
VTP50469 mesylate manufacturers
- VTP50469 mesylate
-
- $2420.00 / 25mg
-
2025-08-21
- CAS:2169919-27-9
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | VTP50469 mesylate Basic information |
| Product Name: | VTP50469 mesylate | | Synonyms: | VTP50469 mesylate;Benzamide, 5-fluoro-N,N-bis(1-methylethyl)-2-[[4-[7-[[trans-4-[(methylsulfonyl)amino]cyclohexyl]methyl]-2,7-diazaspiro[3.5]non-2-yl]-5-pyrimidinyl]oxy]-, compd. with methanesulfonate (1:2) | | CAS: | 2169919-27-9 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![VTP50469 mesylate Structure]() |
| | VTP50469 mesylate Chemical Properties |
| | VTP50469 mesylate Usage And Synthesis |
| Uses | VTP50469 mesylate is a potent, and selective Menin-MLL1 inhibitor that effectively targets MLL-rearranged and NPM1c+ leukemia. VTP50469 mesylate selectively kills cell lines with MLL rearrangements and NPM1c+ mutations. VTP50469 mesylate displaces Menin from protein complexes and inhibits MLL's chromatin occupancy at specific genes, leading to significant changes in gene expression, differentiation, and apoptosis. VTP50469 demonstrates dramatic reductions in leukemia burden in patient-derived xenograft models of MLL-r acute myeloid leukemia and MLL-r acute lymphoblastic leukemia, with some mice remaining disease-free for over a year post-treatment. | | References | [1] A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia DOI:10.1016/j.ccell.2019.11.001 |
| | VTP50469 mesylate Preparation Products And Raw materials |
|